Cerecor Revenue and Competitors
Estimated Revenue & Valuation
- Cerecor's estimated annual revenue is currently $2.6M per year.
- Cerecor's estimated revenue per employee is $77,500
- Cerecor's total funding is $133.3M.
Employee Data
- Cerecor has 33 Employees.
- Cerecor grew their employee count by -23% last year.
Cerecor's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Technical Operations | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Research and Development Programs and Project Management | Reveal Email/Phone |
4 | VP Global Regulatory Affairs | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Research Analyst, Translational Sciences | Reveal Email/Phone |
Cerecor Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Cerecor?
Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.
keywords:N/A
$133.3M
Total Funding
33
Number of Employees
$2.6M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cerecor News
Astraea Therapeutics; LLC; Cerecor Inc. Embera NeuroTherapeutics; Inc. Hager Biosciences; LLC; Heptares Therapeutics Limited; Omeros Corporation; RTI...
Bionex Pharmaceuticals Llc; Cerecor Inc; Chronos Therapeutics Ltd; Corcept Therapeutics Inc; Curemark Llc; Eli Lilly And Company; Ethypharm Sa; H. Lundbeck A/s...
Cerecor Inc; Crescendo Biologics Ltd; Eisai Co Ltd; Inovio Pharmaceuticals Inc. Glutamate Carboxypeptidase 2 Market Breakdown by Type: Ino-5150...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that ...
Cerecor Inc. announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation. With the closing of the second tranche, the Company has drawn down a total of $30 million under its deb ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6M | 33 | -43% | N/A |
#2 | $7.5M | 33 | 3% | N/A |
#3 | $4.8M | 33 | 32% | N/A |
#4 | $4.2M | 33 | 6% | N/A |
#5 | $6.7M | 33 | 0% | N/A |